

NCT ID	NCT05292417
Title	Radiotherapy in Combination With Sintilimab?GM-CSF and Fruquintinib in Patients With MSS mCRC
Phase	Phase 2
Date Added	2022-03-23
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Fruquintinib, GM-CSF, Sintilimab
Tags	MSS/ MMRp
NCT ID	NCT04687631
Title	Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver Metastases
Phase	Phase 3
Date Added	2020-12-29
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	mFOLFOXIRI Plus Bevacizumab, mFOLFOXIRI plus Cetuximab
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	LUMINESCENCE
Title	Ipilimumab, Maraviroc and Nivolumab (LUMINESCENCE)
Phase	Phase 1
Date Added	2019-01-25
Location	
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Ipilimumab, maraviroc, Nivolumab, Celsentri, Opdivo, Selzentry, Yervoy
Tags	MSS/ MMRp
NCT ID	NCT04866862
Title	Fruquintinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer
Phase	Phase 2
Date Added	2021-04-30
Location	China
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Combination of Fruquintinib and Camrelizumab
Tags	MSS/ MMRp
NCT ID	NCT03835949
Title	Study of TJ004309 in Combination With Atezolizumab (Tecentriq(R)) in Patients With Advanced or Metastatic Cancer
Phase	Phase 1
Date Added	2019-02-11

Location	Alabama, United States Arizona, United States California, United States Texas, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Atezolizumab, TJ004309
Tags	MSS/ MMRp
NCT ID	NCT04432857
Title	AN0025 and Pembrolizumab Combination in Advanced Solid Tumors
Phase	Phase 1
Date Added	2020-06-16
Location	Missouri, United States Texas, United States Utah, United States Virginia, United States France
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	AN0025, Pembrolizumab
Tags	MSS/ MMRp
NCT ID	NCT03239145
Title	Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor
Phase	Phase 1
Date Added	2017-08-03
Location	Massachusetts, United States
Prior IO Allowed	No
CRC-directed	Yes
Status	Active, not recruiting
Drugs	Pembrolizumab, Trebananib
Tags	MSS/ MMRp
NCT ID	NCT03494946
Title	Liver Transplantation Compared to Chemotherapy in Patients With ColoRectal Cancer
Phase	Not Applicable
Date Added	2018-04-11
Location	Norway
Prior IO Allowed	No
CRC-directed	Yes
Status	Recruiting
Drugs	Chemotherapy
Tags	MSI-H/ MMRd, MSS/ MMRp
NCT ID	NCT03911557
Title	Durvalumab and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors
Phase	Phase 2
Date Added	2019-04-11
Location	Kentucky, United States

Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Durvalumab and Tremelimumab
Tags	MSS/ MMRp
<hr/>	
NCT ID	NCT03030378
Title	Pembrolizumab and Recombinant Interleukin-12 in Treating Patients With Solid Tumors
Phase	Phase 1
Date Added	2017-01-25
Location	California, United States Colorado, United States Connecticut, United States Florida, United States Georgia, United States Iowa, United States Maryland, United States Massachusetts, United States Missouri, United States New Jersey, United States North Carolina, United States Ohio, United States Pennsylvania, United States Texas, United States Virginia, United States
Prior IO Allowed	No
CRC-directed	No
Status	Active, not recruiting
Drugs	Edodekin alfa, Pembrolizumab
Tags	MSI-H/ MMRd, MSS/ MMRp